Profile

Change your cover photo
Change your cover photo
This user account status is Approved

This user has not added any information to their profile yet.

Sean-Paul
Brankin
Crowell & Moring





Organization Profile

Positions:

Partner, Crowell & Moring
Brussels, Belgium

Experience & Areas of Interest:

Sean-Paul is a Partner in the firm's Brussels office and a member of Crowell & Moring's Antitrust Group. He focuses his practice on issues involving UK and EU antitrust law, including merger control and counselling. Among others, Sean-Paul has extensive experience counseling clients on the IP/antitrust interface and dominance issues across the range of their activities. He has been involved in contentious matters before the European Commission and UK authorities and has litigated cases before the European Community courts, the Competition Appeals Tribunal in the UK and national courts in the UK and elsewhere. Sean-Paul has significant experience working with clients in a number of industries, pharmaceuticals, food and FMCG, chemicals, video games, and financial services.

Sean-Paul taught UK constitutional and administrative law at Kings College London during the academic year of 1993/1994. Before joining Crowell & Moring, Sean-Paul was a Legal Director at the UK Office of Fair Trading where he headed the competition team in the OFT's legal and policy unit and acted as the OFT's lead adviser on UK mergers, with cases including BSkyB/ITV, NASDAQ/LSE and BA/Flybe. Prior to joining the OFT Sean-Paul worked from 1994 in private practise advising on EU and UK antitrust law for Lovells in London and Cleary, Gottlieb, Steen & Hamilton in Brussels and Paris.

Education:

  • Trinity College, Cambridge, B.A., 1991, first class law degree
  • Law University of Virginia School of Law, LL.M., 1992



POST DATE
European Commission Enforcement in the Pharmaceutical Sector: Less Than Expected? The Boehringer Case Closure Suggests As Much
2012-07-27
The AZ Judgment: A Green Light for Further Action on Pharma and IP
2010-09-29
The Pharmaceutical Inquiry: Anything to Report?
2008-11-11